An immunogenic cell death-based signature predicts prognosis and immune landscape in triple-negative breast cancer.
An immune activation signature predicted immunotherapy response in triple-negative breast cancer, guiding tailored treatment design.
Triple-negative breast cancer (TNBC) represents a breast cancer subtype lacking three essential biomarkers: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). It might provide insight into the design of tailored immunotherapies for TNBC.
What the study was
- Study design
- Preclinical study
- Population
- Cancer/disease patients
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Discover oncology
Why it surfaced
Matched topic(s): Novel therapeutics: immunotherapy, CAR-T, targeted therapy. Study design: Preclinical study. Score 6/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.